ProQR Therapeutics
ProQR Therapeutics is a clinical-stage biotech company listed on NASDAQ with offices in Leiden, the Netherlands and Cambridge, MA, US. ProQR is focused on the development of game changing RNA therapies for severe genetic rare diseases. Our mission is to help patients by creating new medicines. A team of 140 ProQRians from all walks of life and more than 30 different nationalities is up to the challenge. We have the passion and commitment to make a difference in the lives of the patients we serve.
- www.proqr.com
- 150
Related Content
- ProQR Announces Recent Progress and Financial Results for the Third Quarter of 2019 Thursday, November 7, 2019
- ProQR Receives Rare Pediatric Disease Designation from FDA for Sepofarsen for the Treatment of LCA10 Friday, October 18, 2019
- ProQR Announces Positive Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients Tuesday, October 15, 2019
- ProQR receives fast track designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa Tuesday, September 10, 2019
- ProQR Announces Clearance of IND to Start Clinical Trial of QR-1123 in Patients with Autosomal Dominant Retinitis Pigmentosa (adRP) Wednesday, August 28, 2019
- European Medicines Agency Grants PRIME Access to ProQR’s Sepofarsen for Leber’s Congenital Amaurosis 10 Monday, July 29, 2019
- ProQR spins out all Dystrophic Epidermolysis Bullosa activities into newly formed Wings Therapeutics Tuesday, March 26, 2019
- ProQR Doses First Patient in Phase 1/2 STELLAR Trial of QR-421a for Usher Syndrome Type 2 Wednesday, March 13, 2019
- ProQR Reaches Agreement with the FDA on Design of Phase 2/3 Pivotal Trial for Sepofarsen (QR-110) for Leber’s Congenital Amaurosis 10 Friday, January 11, 2019
- ProQR announces clearance of IND to start clinical trial of QR-421a in Usher syndrome type 2 patients Wednesday, December 5, 2018
- ProQR In-licenses Worldwide Rights to Ophthalmology Drug Candidate from Ionis Pharmaceuticals Wednesday, October 31, 2018
- ProQR announces positive interim results from phase 1/2 clinical trial of QR-110 in LCA10 patients, and plans to start a phase 2/3 pivotal trial Wednesday, September 5, 2018
- ProQR announces proposed underwritten public offering of ordinary shares Wednesday, September 5, 2018
- ProQR Initiates Phase 1/2 Clinical Trial of QR-313 for Dystrophic Epidermolysis Bullosa Friday, June 29, 2018
- $5 Million for development of QR-313 for the treatment of Dystrophic Epidermolysis Bullosa Tuesday, June 12, 2018
- ProQR Provides Enrollment Update on QR-110 Clinical Trial and Highlights Ophthalmology Presentations at ARVO Monday, April 23, 2018
- ProQR receives orphan drug designation from EMA for drug candidate QR-313 for Dystrophic Epidermolysis Bullosa Wednesday, November 29, 2017
- ProQR doses first LCA 10 patient in clinical trial of QR-110 Monday, November 13, 2017
- ProQR announced positive Top-Line Results from a Phase 1b Study of QR-010 in subjects with Cystic Fibrosis Monday, September 25, 2017
- ProQR receives orphan drug designation from FDA for drug candidate QR-313 for Dystrophic Epidermolysis Bullosa Tuesday, September 19, 2017
- ProQR spins out Amylon Therapeutics as a privately-held company focused on central nervous system (CNS) therapeutics Tuesday, September 12, 2017
- ProQR’s drug candidate QRX-421 for Usher syndrome receives orphan drug designation from FDA and EMA Tuesday, September 5, 2017
- ProQR completes dosing of Cystic Fibrosis patients in QR-010 phase 1b trial Tuesday, August 29, 2017
- ProQR's QRX-411 for Usher syndrome receives orphan drug designation from FDA and EMA Wednesday, July 5, 2017
- ProQR Receives Fast Track Designation from the FDA for QR-110 for Leber’s Congenital Amaurosis Type 10 Wednesday, May 31, 2017
- ProQR announces clearance of IND application to start clinical trial for QR-110 in Leber’s congenital amaurosis Type 10 patients Thursday, April 27, 2017
- ProQR announces the grant of two Key Patents, protecting QR-010 for Cystic Fibrosis in the US and EU Monday, April 3, 2017
- On a shared quest to find treatments for rare diseases Thursday, March 2, 2017
- ProQR Announces that QR-010 Meets the Primary Endpoint in a Proof of Concept Study of Homozygous F508del Cystic Fibrosis Patients Thursday, October 27, 2016
- ProQR receives Fast Track designation from FDA for QR-010 for Cystic Fibrosis Tuesday, July 19, 2016
- ProQR to Release Topline Data from Proof of Concept Study of QR-010 in Cystic Fibrosis Patients at NACFC Tuesday, June 21, 2016
- Eating a sandwich with… Vera Brinks Monday, December 14, 2015
- ProQR announces clearance of IND to start clinical trial of QR-421a in Usher syndrome type 2 patients Thursday, January 1, 1970